Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
NCT07453602
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
125
Enrollment
INDUSTRY
Sponsor class
Conditions
Atopic Dermatitis (AD)
Eczema
Interventions
BIOLOGICAL:
ARQ-234
DRUG:
Placebo
Sponsor
Arcutis Biotherapeutics, Inc.